Kyverna is trying to bring a one-time immune-system “reset” treatment to people with autoimmune diseases, led by executives who have already taken similar therapies from lab to patients. It also has unusually strong partners and a long cash runway, but setbacks in trials or delays in key milestones could quickly change the story.Read more